CAMBRIDGE, Mass., April 13 /PRNewswire/ -- Mersana, a cancer
therapeutics company, announced today that results of preclinical studies
with its lead product candidate, XMT-1001, will be presented in two posters
at the 2007 Annual Meeting of the American Association of Cancer Research
(AACR) taking place April 14-18th in Los Angeles, CA. Full text of the
abstracts can be viewed online at the AACR website at http://www.AACR.org.
The presentation schedule is as follows:
Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is
a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse
model" will be presented in a poster session on Sunday, April 15th from
8:00 am - 12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the
presenting authors.
Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate
(XMT- 1001) in the rat and dog" will be presented in a poster session on
Tuesday, April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex
Yurkovetskiy are the presenting authors.
About XMT-1101
XMT-1001 is Mersana's most advanced Fleximer(R)-based product
candidate. It utilizes a novel, dual release mechanism to liberate a
camptothecin prodrug, which is then converted within cells into
camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies,
XMT-1001 was better tolerated and more efficacious than either camptothecin
or irinotecan in models of human cancer, showing extended plasma half-life
and high concentrations in tumor tissue.
About Fleximer Technology
Fleximer(R) technology improves the therapeutic index of cytotoxic
compounds useful as anti-cancer agents by uniquely combining
biodegradability with "biological stealth" properties, making Fleximer(R)
materials and their conjugates long-circulating and non-immunotoxic.
Fleximer(R) molecules are characterized by solubility in water, stability
in common manufacturing procedures and in normal physiological conditions,
and non-enzymatic biodegradability upon uptake by cells.
About Mersana Therapeutics, Inc.
Mersana, a privately held, venture-backed company, is developing novel
oncology agents based on clinically validated drugs through the use of
Fleximer(R), a proprietary bio-degradable and bio-inert material that
enhances the pharmacokinetics, safety, and solubility of drugs. Mersana has
an exclusive license from the Massachusetts General Hospital for its core
technologies. Mersana's pipeline includes compounds with activity against
multiple tumor types and human proof-of-concept that are improved by its
proprietary technologies. Mersana's investors include Fidelity Biosciences,
ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech
Ventures.
SOURCE Mersana Therapeutics, Inc.
 back to top
Related links:
http://www.AACR.org
CONTACT:
Pete Leone, COO of Mersana, +1-617-498-0020
|
